Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Scalable Gastric Resident Systems for Veterinary Application.

Hayward A, Bensel T, Mazdiyasni H, Rogner J, Kirtane AR, Lee YL, Hua T, Bajpayee A, Collins J, McDonnell S, Cleveland C, Lopes A, Wahane A, Langer R, Traverso G.

Sci Rep. 2018 Aug 7;8(1):11816. doi: 10.1038/s41598-018-30212-3.

2.

Genotype-targeted local therapy of glioma.

Shankar GM, Kirtane AR, Miller JJ, Mazdiyasni H, Rogner J, Tai T, Williams EA, Higuchi F, Juratli TA, Tateishi K, Koerner MVA, Tummala SS, Fink AL, Penson T, Schmidt SP, Wojtkiewicz GR, Baig A, Francis JM, Rinne ML, Batten JM, Batchelor TT, Brastianos PK, Curry WT Jr, Barker FG 2nd, Jordan JT, Iafrate AJ, Chi AS, Lennerz JK, Meyerson M, Langer R, Wakimoto H, Traverso G, Cahill DP.

Proc Natl Acad Sci U S A. 2018 Sep 4;115(36):E8388-E8394. doi: 10.1073/pnas.1805751115. Epub 2018 Aug 6.

PMID:
30082399
3.

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy.

Kirtane AR, Abouzid O, Minahan D, Bensel T, Hill AL, Selinger C, Bershteyn A, Craig M, Mo SS, Mazdiyasni H, Cleveland C, Rogner J, Lee YL, Booth L, Javid F, Wu SJ, Grant T, Bellinger AM, Nikolic B, Hayward A, Wood L, Eckhoff PA, Nowak MA, Langer R, Traverso G.

Nat Commun. 2018 Jan 9;9(1):2. doi: 10.1038/s41467-017-02294-6.

4.

Triggerable tough hydrogels for gastric resident dosage forms.

Liu J, Pang Y, Zhang S, Cleveland C, Yin X, Booth L, Lin J, Lucy Lee YA, Mazdiyasni H, Saxton S, Kirtane AR, Erlach TV, Rogner J, Langer R, Traverso G.

Nat Commun. 2017 Jul 25;8(1):124. doi: 10.1038/s41467-017-00144-z.

5.

Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals.

Bellinger AM, Jafari M, Grant TM, Zhang S, Slater HC, Wenger EA, Mo S, Lee YL, Mazdiyasni H, Kogan L, Barman R, Cleveland C, Booth L, Bensel T, Minahan D, Hurowitz HM, Tai T, Daily J, Nikolic B, Wood L, Eckhoff PA, Langer R, Traverso G.

Sci Transl Med. 2016 Nov 16;8(365):365ra157.

6.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF.

J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. doi: 10.1124/jpet.113.203489. Epub 2013 May 24.

7.

Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kα.

Nacht M, Qiao L, Sheets MP, St Martin T, Labenski M, Mazdiyasni H, Karp R, Zhu Z, Chaturvedi P, Bhavsar D, Niu D, Westlin W, Petter RC, Medikonda AP, Singh J.

J Med Chem. 2013 Feb 14;56(3):712-21. doi: 10.1021/jm3008745. Epub 2013 Feb 5.

PMID:
23360348
8.

Novel IKK inhibitors: beta-carbolines.

Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, Parent L, Pien C, Palombella V, Adams J.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22.

PMID:
12824047
9.

Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.

Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FA, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CD.

J Med Chem. 1997 Jun 20;40(13):1955-68.

PMID:
9207936
10.

Structure-based design of substituted diphenyl sulfones and sulfoxides as lipophilic inhibitors of thymidylate synthase.

Jones TR, Webber SE, Varney MD, Reddy MR, Lewis KK, Kathardekar V, Mazdiyasni H, Deal J, Nguyen D, Welsh KM, Webber S, Johnston A, Matthews DA, Smith WW, Janson CA, Bacquet RJ, Howland EF, Booth CL, Herrmann SM, Ward RW, White J, Bartlett CA, Morse CA.

J Med Chem. 1997 Feb 28;40(5):677-83.

PMID:
9057854
11.

Adenosine kinase inhibition protects brain against transient focal ischemia in rats.

Jiang N, Kowaluk EA, Lee CH, Mazdiyasni H, Chopp M.

Eur J Pharmacol. 1997 Feb 12;320(2-3):131-7.

PMID:
9059845
12.

Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.

Summers JB, Kim KH, Mazdiyasni H, Holms JH, Ratajczyk JD, Stewart AO, Dyer RD, Carter GW.

J Med Chem. 1990 Mar;33(3):992-8.

PMID:
2308149
13.

Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis.

Summers JB, Gunn BP, Martin JG, Martin MB, Mazdiyasni H, Stewart AO, Young PR, Bouska JB, Goetze AM, Dyer RD, et al.

J Med Chem. 1988 Oct;31(10):1960-4.

PMID:
3172130
14.

Orally active hydroxamic acid inhibitors of leukotriene biosynthesis.

Summers JB, Gunn BP, Martin JG, Mazdiyasni H, Stewart AO, Young PR, Goetze AM, Bouska JB, Dyer RD, Brooks DW, et al.

J Med Chem. 1988 Jan;31(1):3-5. No abstract available.

PMID:
3336029
15.

In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.

Summers JB, Gunn BP, Mazdiyasni H, Goetze AM, Young PR, Bouska JB, Dyer RD, Brooks DW, Carter GW.

J Med Chem. 1987 Nov;30(11):2121-6.

PMID:
3669019
16.

Hydroxamic acid inhibitors of 5-lipoxygenase.

Summers JB, Mazdiyasni H, Holms JH, Ratajczyk JD, Dyer RD, Carter GW.

J Med Chem. 1987 Mar;30(3):574-80.

PMID:
3820229

Supplemental Content

Loading ...
Support Center